novo nordisk semaglutide pill FDA approves oral Rybelsus to treat type 2 diabetes Novo Nordisk says Wegovy beats

In December 2025, the administration also introduced the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) model, a five year CMS Innovation Center (CMMI) model that intends to expand access to obesity drugs in Medicaid and Medicare by negotiating lower GLP-1 prices with manufacturers

One notable barrier is that GLP-1 receptor agonists have historically been administered via SC injection only

For a closer look at the broader medication class, see our guide on what GLP-1 medications are

Not available to Molina Medicaid or Medicare beneficiaries

Step-by-step injection day protocol Theory matters

Researchers believe that engaging the GIP receptor alongside GLP-1 may improve the bodys response to insulin and contribute to the stronger weight-loss results seen with tirzepatide